Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to TIL therapy improved response rates among individuals with metastatic ...

In a recent review published in Nature Reviews Immunology, researchers elucidated the mechanisms of long-term T lymphocyte lodgement in tissues other than lymphoid tissues and the reasons for the ...

The use of a tumor-infiltrating lymphocyte therapy led to better outcomes than treatment with Yervoy in patients with unresectable, treatment-refractory stage 3/4 melanoma, a type of skin cancer, ...

A small trial by investigators at the National Cancer Institute holds promise to bring personalized cell therapy into the solid tumor arena, after more than a decade of success in blood cancers. A new ...